Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
homogeneous anti-EGFR ADC 1
- Development stage
- Preclinical
- Lead developer
- Ajou University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Homogeneous anti-EGFR ADC 1 is an experimental antibody-drug conjugate (ADC) designed for the treatment of glioblastoma multiforme (GBM). It consists of the anti-EGFR monoclonal antibody cetuximab site-specifically conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) using the AbClick technology. This specific construct is characterized by its high homogeneity and a defined drug-to-antibody ratio (DAR) of 2. Research indicates that these parameters are critical for overcoming the blood-brain barrier (BBB), as lower-DAR homogeneous species demonstrate superior brain tumor penetration and therapeutic efficacy compared to heterogeneous or highly loaded ADCs. In preclinical studies, it has shown significant survival benefits in orthotopic brain tumor models by optimizing payload delivery to intracranial tumors.
- Other names
- Cetuximab-vcMMAE (DAR 2)AbClick-EGFR-ADChomogeneous DAR2 anti-EGFR ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on homogeneous anti-EGFR ADC 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on homogeneous anti-EGFR ADC 1.